Sentence examples for modification and discontinuation from inspiring English sources

41 As skin toxicity may result in dose modification and discontinuation, optimizing management of skin toxicity is paramount.

By adjusting the dose according to the criteria for dose modification and discontinuation (Tables  1, 2), the XP regimen permits the continuation of treatment when adverse reactions occur.

High rates of dose modification and discontinuation were observed with nab-paclitaxel 150 mg/m monotherapy qw 3/4 in a phase II trial and with nab-paclitaxel 150 mg/m qw 3/4 plus bevacizumab in a phase III trial [ 29, 30, 33].

Associations between predictors and treatment modification and discontinuation because of low-grade toxicity were investigated with univariate analysis using χ or Fisher's exact test if the expected frequency was less than 5. SPSS version 19 statistical software package (SPSS, Inc., Chicago, IL, USA) was used for data analysis.

Table 3 demonstrates univariate associations of age, comorbidity, PS and treatment intent with low-grade toxicity (vs high) resulting in treatment modifications and discontinuation.

Further, we wanted to describe the frequency of treatment modifications and discontinuations, as well as the clinical course.

Comparability across study groups can be improved, and subjectivity in care decisions reduced, by defining standard criteria for intervention modifications and discontinuations in the protocol.

This study provided evidence through a comprehensive review of medical charts for 291 advanced RCC patients across key institutions in five European countries that severe AEs were significantly correlated with lower dose intensities, and that AEs were frequently cited as reasons for treatment modifications and discontinuations.

The purpose of this observational cohort study was to identify which level of toxicity triggers treatment modification and early discontinuation of chemotherapy in older people.

Of the 661 patients, 181 (27.4%) were non-adherence to treatment, and of these, 82 (45.3%) and 99 (54.7%) experienced dose modification and drug discontinuation, respectively, with no significant intergroup difference (Table  4).

Higher incidences of AEs, dose modifications, and treatment discontinuation among EVE-treated patients may, in part, be attributed to the longer treatment duration in the EVE+EXE arm.